Diphtheria– Pipeline Review, 2024

Diphtheria is a contagious disease caused by bacterium Corynebacterium diphtheria that infects the mucous membranes of nose, throat, upper airway tracts and produces toxins that affect the other organs. The diphtheria toxin causes the membrane of dead tissue to build up over the throat that makes swallowing and breathing of the patient difficult. Diphtheria is caused only among humans and spreads easily through physical contact with the affected person. The symptoms of diphtheria are fever, swollen glands in the neck, a sore throat, bluish skin, and weakness. Complications of diphtheria include blockage of the airway, damage to heart muscles, lung infection, and others.

Currently, the treatment for diphtheria includes intervention of antitoxin or antibiotics. Erythromycin is the first-line therapy. Intramuscular penicillin and diphtheria antitoxin are further recommended at a later stage of the disease. Vaccination against diphtheria has been the most effective way of treatment and prevention of the disease. Vaccines available are DTaP, Tdap, DT, and Td. DTap is a vaccine for pediatrics, whereas Tdap is an adult vaccine.

Awareness about prevention of diphtheria in patients and demand for more vaccinations against the disease is boosting the pharmaceutical industries to accelerate their R&D in the development of effective vaccines for the treatment of diphtheria. For instance; GSK2036874A vaccine is being studied by GlaxoSmithKline Plc. and is currently in phase-2 clinical-stage to evaluate the immunogenicity, safety, and efficacy of the vaccine in treatment of diphtheria.

To know how our report can help streamline your business, Speak to Analyst

At present, around 54% of the pipeline candidates for diphtheria are in phase 3 clinical stage. Pharmaceutical industries are the major sponsor for research on diphtheria.

Report Description

The report on ‘Diphtheria– Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Diphtheria. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for diabetic neuropathic pain.

The report on ‘Diphtheria– Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Diphtheria
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Diphtheria
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary